Afatinib followed by osimertinib in patients with EGFR mutation-positive (EGFRm plus ) advanced NSCLC: Updated data from the GioTag real-world study

被引：0

作者：

Hochmair, M. J. ^{[1
,2
]}

Morabito, A. ^{[3
]}

Hao, D. ^{[4
]}

Yang, C-T. ^{[5
]}

Soo, R. ^{[6
]}

Yang, J. C-H. ^{[7
]}

Gucalp, R. ^{[8
]}

Halmos, B. ^{[8
]}

Wang, L. ^{[9
]}

Golembesky, A. ^{[10
]}

Maerten, A. ^{[10
]}

Cufer, T. ^{[11
]}

机构：

[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[2] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria

[3] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, Naples, Italy

[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[5] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan

[6] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore

[7] Natl Taiwan Univ, Canc Ctr, Natl Taiwan Univ Hosp, Taipei, Taiwan

[8] Montefiore Albert Einstein Canc Ctr, Dept Oncol, New York, NY USA

[9] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan

[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[11] Univ Ljubljana, Univ Clin Golnik, Ljubljana, Slovenia

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1532P

引用

下载

页数：1

共 50 条

[1] Afatinib followed by osimertinib in patients with EGFR mutation-positive advanced NSCLC: A real-world study (GioTag)
Hochmair, M. J.
Morabito, A.
Hao, D.
Yang, C-T.
Soo, R. A.
Yang, J. C-H.
Gucalp, R.
Halmos, B.
Wang, L.
Golembesky, A.
Maerten, A.
Cufer, T.
ANNALS OF ONCOLOGY, 2018, 29
[2] Afatinib Followed by Osimertinib in Real-World Patients with EGFR Mutation-Positive Advanced NSCLC: The Giotag Study
Hochmair, M. J.
Morabito, A.
Hao, D.
Yang, C.
Soo, R.
Yang, J. C.
Gucalp, R.
Halmos, B.
Golembesky, A.
Maerten, A.
Cufer, T.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1045 - S1045
[3] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
Hochmair, M.
Cufer, T.
Morabito, A.
Hao, D.
Yang, C. Ta
Soo, R.
Yang, J.
Gucalp, R.
Halmos, B.
Wang, L.
Golembesky, A.
Maerten, A.
O'Byrne, K.
LUNG CANCER, 2019, 127 : S59 - S60
[4] Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study
Hochmair, M.
Cufer, T.
Morabito, A.
Hao, D.
Yang, C.
Soo, R.
Yang, J. C.
Gucalp, R. Rasim
Halmos, B.
Wang, L.
Golembesky, A.
Maerten, A.
O'Byrne, K.
LUNG CANCER, 2019, 127 : S37 - S37
[5] Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm plus ) NSCLC: Final analysis of Asian patients in the GioTag study
Hochmair, M. J.
Morabito, A.
Hao, D.
Yang, C-T.
Soo, R. A.
Yang, J. C-H.
Gucalp, R.
Halmos, B.
Marten, A.
Cufer, T.
ANNALS OF ONCOLOGY, 2020, 31 : S1399 - S1399
[6] UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm plus ) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Miura, S.
Maerten, A.
Popat, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1405 - S1406
[7] Real-world dose adjustment study of first-line afatinib in pts with EGFR mutation-positive (EGFRm plus ) advanced NSCLC.
Halmos, Balazs
Tan, Eng-Huat
Lee, Min Ki
Foucher, Pascal
Hsia, Te-Chun
Hochmair, Maximilian J.
Griesinger, Frank
Hida, Toyoaki
Kim, Edward S.
Melosky, Barbara L.
Maerten, Angela
Costa, Enric Carcereny
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommon mutations: Experience in 'Real-World' clinical practice
Maerten, Angela
Brueckl, Wolfgang
Laack, Eckhart
Hoffmann, Christopher
Zhou, Caicun
Wu, Yi-Long
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 160
[9] Afatinib in EGFR Mutation-Positive (EGFRm plus ) NSCLC Harbouring Uncommon Mutations: Experience in 'Real-World' Clinical Practice
Brueckl, W.
Laack, E.
Hoffmann, C.
Zhou, C.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S670 - S671
[10] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
Wehler, T.
Wehler, B.
Atmaca-Dirik, H.
Schulz, C.
Grohe, C.
Topsch, J.
Ehrlich, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801

← 1 2 3 4 5 →